What is Castle Biosciences' operating income?

Castle Biosciences' total operating income in 2025 was -$42.81 million, based on the following breakdown: Total Gross Profit: $273.20 million Total Operating Expenses: $316.01 million

Castle Biosciences (CSTL) Financials

$23.72 -0.84 (-3.42%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$23.72 0.00 (0.00%)

As of 07/10/2026 04:10 PM Eastern

Compare

Annual Income Statements for Castle Biosciences

This table shows Castle Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	2.99	-10	-31	-69	-57	18	-24
Consolidated Net Income / (Loss)	5.28	-10	-31	-67	-57	18	-24
Net Income / (Loss) Continuing Operations	5.28	-10	-31	-67	-57	18	-24
Total Pre-Tax Income	5.35	-10	-40	-69	-57	22	-30
Total Operating Income	7.33	-6.54	-40	-73	-68	8.67	-43
Total Gross Profit	45	53	78	105	175	272	273
Total Revenue	52	63	94	137	220	332	344
Operating Revenue	52	63	94	137	220	332	344
Total Cost of Revenue	7.31	9.69	16	32	45	60	71
Operating Cost of Revenue	7.31	9.69	16	32	45	60	71
Total Operating Expenses	37	60	118	178	243	263	316
Selling, General & Admin Expense	30	48	87	143	180	200	229
Research & Development Expense	7.39	13	30	45	54	52	52
Amortization Expense	-	0.00	1.96	8.27	9.01	11	35
Total Other Income / (Expense), net	-1.98	-3.66	0.07	3.95	11	13	13
Interest Expense	-0.64	4.03	0.00	0.02	0.01	0.58	0.09
Interest & Investment Income	0.31	0.37	0.07	3.97	11	13	13
Other Income / (Expense), net	-2.93	-	0.00	0.00	0.00	0.00	0.14
Income Tax Expense	0.07	0.08	-8.72	-1.77	0.10	3.32	-5.36
Basic Earnings per Share	$0.35	($0.54)	($1.24)	($2.58)	($2.14)	$0.66	($0.83)
Weighted Average Basic Shares Outstanding	8.58M	18.93M	25.14M	26.05M	26.80M	27.78M	28.99M
Diluted Earnings per Share	($0.21)	($0.54)	($1.24)	($2.58)	($2.14)	$0.62	($0.83)
Weighted Average Diluted Shares Outstanding	8.66M	18.93M	25.14M	26.05M	26.80M	29.26M	28.99M
Weighted Average Basic & Diluted Shares Outstanding	-	24.98M	25.41M	26.58M	27.45M	28.51M	29.73M
Cash Dividends to Common per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00

This table shows Castle Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-6.87	-2.54	-2.49	8.92	2.27	9.59	-26	4.52	-0.50	-1.91	-14
Consolidated Net Income / (Loss)	-6.91	-2.58	-2.53	8.92	2.27	9.59	-26	4.52	-0.50	-2.33	-15
Net Income / (Loss) Continuing Operations	-6.91	-2.58	-2.53	8.92	2.27	9.59	-26	4.52	-0.50	-2.33	-15
Total Pre-Tax Income	-6.87	-2.54	-2.49	7.89	8.28	7.89	-26	-0.14	-0.39	-2.71	-14
Total Operating Income	-9.64	-5.66	-5.47	5.01	5.08	4.05	-28	-4.25	-6.80	-3.83	-18
Total Gross Profit	50	54	59	72	70	70	72	69	64	69	63
Total Revenue	61	66	73	87	86	86	88	86	83	87	84
Operating Revenue	61	66	73	87	86	86	88	86	83	87	84
Total Cost of Revenue	11	12	14	15	16	16	16	18	19	18	21
Operating Cost of Revenue	11	12	14	15	16	16	16	18	19	18	21
Total Operating Expenses	60	59	65	67	65	66	100	73	71	73	82
Selling, General & Admin Expense	45	44	48	51	50	50	59	58	56	57	65
Research & Development Expense	13	13	14	14	12	12	13	13	13	14	14
Amortization Expense	2.27	2.27	2.25	2.25	2.27	4.34	28	1.96	2.28	2.28	2.23
Total Other Income / (Expense), net	2.77	3.12	2.98	2.87	3.20	3.84	1.66	4.11	6.42	1.11	3.99
Interest Expense	0.00	0.00	0.01	0.27	0.20	0.09	0.02	0.02	0.02	0.02	0.13
Interest & Investment Income	2.77	3.12	3.00	3.14	3.40	3.37	3.10	2.94	6.39	0.80	2.55
Other Income / (Expense), net	-	-	0.00	0.00	0.00	-	-1.43	1.19	0.05	0.34	1.58
Income Tax Expense	0.03	0.04	0.05	-1.03	6.01	-1.71	-0.42	-4.67	0.12	-0.38	0.11
Basic Earnings per Share	($0.26)	($0.08)	($0.09)	$0.32	$0.08	$0.35	($0.90)	$0.16	($0.02)	($0.07)	($0.49)
Weighted Average Basic Shares Outstanding	26.83M	26.80M	27.49M	27.65M	27.84M	27.78M	28.61M	28.91M	29.07M	28.99M	29.89M
Diluted Earnings per Share	($0.26)	($0.08)	($0.09)	$0.31	$0.08	$0.32	($0.90)	$0.15	($0.02)	($0.06)	($0.49)
Weighted Average Diluted Shares Outstanding	26.83M	26.80M	27.49M	28.74M	29.40M	29.26M	28.61M	29.55M	29.07M	28.99M	29.89M
Weighted Average Basic & Diluted Shares Outstanding	26.91M	27.45M	27.61M	27.74M	28.01M	28.51M	28.87M	29.01M	29.19M	29.73M	30.33M

This table details how cash moves in and out of Castle Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	94	311	-80	-207	-24	21	-2.98
Net Cash From Operating Activities	7.02	9.87	-19	-42	-5.63	65	64
Net Cash From Continuing Operating Activities	7.02	9.87	-19	-42	-5.63	65	64
Net Income / (Loss) Continuing Operations	5.28	-10	-31	-67	-57	18	-24
Consolidated Net Income / (Loss)	5.28	-10	-31	-67	-57	18	-24
Depreciation Expense	0.35	0.47	3.41	11	12	16	41
Amortization Expense	1.93	0.84	0.00	-1.37	-5.49	-6.69	-4.22
Non-Cash Adjustments To Reconcile Net Income	-0.59	18	13	36	52	51	46
Changes in Operating Assets and Liabilities, net	0.04	0.80	-3.64	-20	-6.60	-14	6.00
Net Cash From Investing Activities	-0.94	-4.75	-67	-167	-16	-50	-60
Net Cash From Continuing Investing Activities	-0.94	-4.75	-67	-167	-16	-50	-60
Purchase of Property, Plant & Equipment	-0.94	-4.75	-3.48	-5.63	-14	-28	-36
Acquisitions	-	0.00	-63	-26	0.00	0.00	-19
Purchase of Investments	-	-	0.00	-135	-189	-206	-196
Sale of Property, Plant & Equipment	0.00	0.00	0.01	0.20	0.01	0.02	0.05
Sale and/or Maturity of Investments	-	-	-	0.00	187	184	191
Net Cash From Financing Activities	88	306	5.42	1.52	-2.30	6.14	-6.96
Net Cash From Continuing Financing Activities	88	306	5.42	1.52	-2.30	6.14	-6.96
Repayment of Debt	-1.79	-27	-0.01	-0.12	-0.14	-0.10	-0.12
Issuance of Debt	23	-	-	0.00	0.00	10	0.00
Issuance of Common Equity	66	332	2.31	2.49	2.71	2.98	2.42
Other Financing Activities, net	1.22	1.59	3.45	-0.86	-4.87	-6.75	-9.26
Cash Interest Paid	2.21	1.98	0.00	0.02	0.01	0.43	0.06
Cash Income Taxes Paid	-0.15	0.10	0.02	0.12	0.20	2.50	1.60

This table details how cash moves in and out of Castle Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-4.65	7.62	-16	2.62	9.39	25	-30	-7.46	3.32	31	-53
Net Cash From Operating Activities	5.01	19	-6.84	24	23	24	-6.04	21	23	27	-22
Net Cash From Continuing Operating Activities	5.01	19	-6.84	24	23	24	-6.04	21	23	27	-22
Net Income / (Loss) Continuing Operations	-6.91	-2.58	-2.53	8.92	2.27	9.59	-26	4.52	-0.50	-2.33	-15
Consolidated Net Income / (Loss)	-6.91	-2.58	-2.53	8.92	2.27	9.59	-26	4.52	-0.50	-2.33	-15
Depreciation Expense	3.17	3.22	3.34	3.35	3.54	5.77	30	3.41	3.82	3.78	3.93
Amortization Expense	-1.57	-1.64	-1.70	-1.72	-1.65	-1.61	-1.44	-1.17	-0.91	-0.71	-0.45
Non-Cash Adjustments To Reconcile Net Income	13	12	13	13	13	11	12	10	8.95	13	8.66
Changes in Operating Assets and Liabilities, net	-2.68	7.10	-19	0.03	5.70	-0.64	-21	3.60	11	13	-20
Net Cash From Investing Activities	-9.71	-7.67	-20	-21	-15	5.77	-22	-28	-18	8.83	-26
Net Cash From Continuing Investing Activities	-9.71	-7.67	-20	-21	-15	5.77	-22	-28	-18	8.83	-26
Purchase of Property, Plant & Equipment	-2.46	-3.79	-9.15	-5.23	-6.38	-7.57	-4.74	-9.26	-15	-7.18	-12
Purchase of Investments	-50	-52	-61	-52	-45	-47	-54	-44	-58	-40	-55
Sale of Property, Plant & Equipment	0.00	0.00	0.01	0.00	0.00	0.01	0.01	0.01	0.02	0.01	0.01
Sale and/or Maturity of Investments	43	49	50	36	37	61	36	44	55	56	42
Net Cash From Financing Activities	0.05	-3.30	11	0.04	0.84	-5.39	-1.55	0.10	-0.92	-4.59	-5.03
Net Cash From Continuing Financing Activities	0.05	-3.30	11	0.04	0.84	-5.39	-1.55	0.10	-0.92	-4.59	-5.03
Repayment of Debt	-0.04	-0.04	-0.04	-0.01	-0.02	-0.03	-0.03	-0.03	-0.03	-0.03	-0.02
Issuance of Common Equity	0.34	0.68	1.09	0.66	0.59	0.65	0.97	0.51	0.22	0.71	1.27
Other Financing Activities, net	-0.26	-3.94	-0.41	-0.61	0.28	-6.01	-2.50	-0.38	-1.11	-5.28	-6.28

This table presents Castle Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	22	120	439	463	447	453	531	579
Total Current Assets	18	117	430	354	292	296	360	361
Cash & Equivalents	4.48	99	410	330	123	99	120	117
Short-Term Investments	-	-	-	0.00	136	144	173	183
Accounts Receivable	12	15	13	17	23	38	51	43
Inventories, net	0.88	1.24	2.22	2.02	3.98	7.94	8.14	10
Prepaid Expenses	0.68	1.95	4.77	4.81	6.21	6.29	7.67	7.96
Plant, Property, & Equipment, net	1.53	2.06	0.00	9.50	14	25	51	97
Total Noncurrent Assets	2.75	1.01	9.73	99	141	132	120	120
Noncurrent Note & Lease Receivables	2.53	0.87	1.10	1.31	1.09	1.19	0.92	1.88
Goodwill	-	-	-	89	126	117	106	100
Other Noncurrent Operating Assets	0.21	0.14	8.64	9.10	13	14	13	19
Total Liabilities & Shareholders' Equity	22	120	439	463	447	453	531	579
Total Liabilities	32	35	24	51	48	62	75	108
Total Current Liabilities	6.74	15	21	25	36	48	49	69
Short-Term Debt	0.00	5.83	-	-	-	0.00	0.28	0.42
Accounts Payable	1.45	1.87	2.10	2.55	4.73	10	6.90	19
Accrued Expenses	0.72	1.81	3.06	5.68	5.26	7.32	7.99	8.94
Current Employee Benefit Liabilities	4.57	5.78	9.11	15	24	29	33	38
Other Current Liabilities	-	0.00	6.62	1.18	1.78	1.14	1.67	2.33
Total Noncurrent Liabilities	26	19	2.76	26	12	14	26	39
Long-Term Debt	24	19	-	-	-	0.00	9.75	9.64
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	0.00	0.64	0.43	0.21	1.61	2.34
Other Noncurrent Operating Liabilities	1.19	-	2.76	25	12	14	15	27
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-57	85	416	412	399	391	456	471
Total Preferred & Common Equity	-57	85	416	412	399	391	456	471
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-57	85	416	412	399	391	456	471
Common Stock	0.92	137	478	506	560	610	656	695
Retained Earnings	-57	-52	-62	-94	-161	-218	-200	-224
Accumulated Other Comprehensive Income / (Loss)	-	-	-	0.00	-0.38	0.14	0.23	0.27

This table presents Castle Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	458	427	425	436	459	487	515	502	545	563	548
Total Current Assets	299	271	269	280	296	320	345	349	349	358	329
Cash & Equivalents	134	115	96	91	83	86	95	90	82	86	64
Short-Term Investments	132	117	130	139	156	174	185	185	194	202	198
Accounts Receivable	23	28	31	37	43	46	50	56	52	49	42
Inventories, net	3.80	4.52	6.12	5.77	7.65	8.01	6.57	6.85	8.37	8.65	10
Prepaid Expenses	6.80	6.80	6.11	7.10	6.22	6.72	8.15	11	12	12	14
Plant, Property, & Equipment, net	13	18	21	22	33	39	44	55	0.00	85	101
Total Noncurrent Assets	145	138	136	134	130	128	125	97	196	120	118
Noncurrent Note & Lease Receivables	1.19	1.22	1.23	1.34	1.06	1.13	1.11	1.00	1.13	2.05	1.92
Goodwill	130	124	122	120	115	113	111	78	104	102	97
Other Noncurrent Operating Assets	14	12	13	13	14	14	14	12	91	16	19
Total Liabilities & Shareholders' Equity	458	427	425	436	459	487	515	502	545	563	548
Total Liabilities	46	42	47	50	56	63	74	61	89	96	86
Total Current Liabilities	32	30	34	36	32	39	44	37	51	55	49
Short-Term Debt	-	-	-	-	-	-	-	1.11	1.94	0.00	1.67
Accounts Payable	5.77	9.96	7.14	6.93	9.32	9.54	6.81	8.50	13	12	15
Accrued Expenses	5.11	5.61	7.32	5.90	6.74	7.45	8.07	8.37	8.22	8.89	11
Current Employee Benefit Liabilities	20	13	17	22	15	21	28	18	25	32	19
Other Current Liabilities	1.54	1.78	1.97	1.09	1.19	1.23	1.75	1.44	2.57	2.45	2.25
Total Noncurrent Liabilities	14	12	13	14	24	24	29	24	38	40	38
Long-Term Debt	-	-	-	-	10	10	10	8.92	8.10	10	8.40
Noncurrent Deferred & Payable Income Tax Liabilities	0.61	0.44	0.44	0.44	0.21	0.00	4.22	0.84	3.13	3.24	2.33
Other Noncurrent Operating Liabilities	14	11	12	13	14	14	15	14	27	27	27
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	411	385	379	386	402	424	441	440	455	467	461
Total Preferred & Common Equity	411	385	379	386	402	424	441	440	455	467	461
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	411	385	379	386	402	424	441	440	455	467	461
Common Stock	552	575	588	602	623	636	650	666	677	689	700
Retained Earnings	-140	-190	-209	-216	-221	-212	-210	-226	-221	-222	-239
Accumulated Other Comprehensive Income / (Loss)	-0.19	-0.14	-0.14	-0.07	-0.11	-0.17	0.47	0.13	0.04	0.24	-0.06

This table displays calculated financial ratios and metrics derived from Castle Biosciences' official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	17,074,049.00	19,911,225.00	25,300,343.00	-	-	-	29,188,659.00
DEI Adjusted Shares Outstanding	17,074,049.00	19,911,225.00	25,300,343.00	-	-	-	29,188,659.00
DEI Earnings Per Adjusted Shares Outstanding	0.18	-0.52	-1.24	-	-	-	-0.83
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	20.79%	50.18%	45.65%	60.38%	51.09%	3.66%
EBITDA Growth	0.00%	-178.33%	-601.05%	-73.65%	3.99%	130.32%	-134.00%
EBIT Growth	0.00%	-248.85%	-512.64%	-81.78%	6.70%	113.57%	-592.11%
NOPAT Growth	0.00%	-163.34%	-512.64%	-81.78%	6.70%	115.42%	-508.52%
Net Income Growth	0.00%	-294.88%	-204.28%	-114.55%	14.41%	131.75%	-232.41%
EPS Growth	0.00%	-157.14%	-129.63%	-108.06%	17.05%	128.97%	-233.87%
Operating Cash Flow Growth	0.00%	40.63%	-292.43%	-119.43%	86.49%	1,252.97%	-0.80%
Free Cash Flow Firm Growth	0.00%	0.00%	-10,837.27%	-4.88%	49.52%	68.82%	-124.50%
Invested Capital Growth	0.00%	-48.74%	1,306.18%	71.15%	5.44%	16.57%	5.04%
Revenue Q/Q Growth	0.00%	0.00%	8.96%	10.75%	14.47%	6.47%	0.20%
EBITDA Q/Q Growth	0.00%	0.00%	-42.97%	-13.26%	21.86%	225.04%	-299.28%
EBIT Q/Q Growth	0.00%	0.00%	-43.45%	-11.75%	20.17%	988.73%	-23.42%
NOPAT Q/Q Growth	0.00%	0.00%	-43.45%	-11.75%	20.17%	1,395.68%	-22.55%
Net Income Q/Q Growth	0.00%	0.00%	-5.18%	-26.80%	23.89%	200.33%	-97.43%
EPS Q/Q Growth	0.00%	0.00%	0.80%	-25.85%	24.65%	181.82%	-84.44%
Operating Cash Flow Q/Q Growth	0.00%	-33.29%	-14.14%	-8.38%	81.38%	9.78%	4.15%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	23.24%	21.31%	-8.86%	9.50%
Invested Capital Q/Q Growth	0.00%	0.00%	69.17%	-3.39%	-5.04%	0.84%	-4.29%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	85.91%	84.54%	83.18%	76.64%	79.53%	81.87%	79.37%
EBITDA Margin	12.88%	-8.35%	-38.98%	-46.47%	-27.82%	5.58%	-1.78%
Operating Margin	14.13%	-10.44%	-42.60%	-53.16%	-30.93%	2.61%	-12.44%
EBIT Margin	8.47%	-10.44%	-42.60%	-53.16%	-30.93%	2.78%	-12.39%
Profit (Net Income) Margin	10.17%	-16.42%	-33.26%	-48.99%	-26.15%	5.49%	-7.02%
Tax Burden Percent	98.65%	100.82%	78.21%	97.44%	100.18%	84.61%	81.85%
Interest Burden Percent	121.71%	155.92%	99.83%	94.58%	84.39%	233.76%	69.17%
Effective Tax Rate	1.35%	0.00%	0.00%	0.00%	0.00%	15.39%	0.00%
Return on Invested Capital (ROIC)	63.47%	-53.16%	-63.80%	-45.81%	-32.96%	4.57%	-16.92%
ROIC Less NNEP Spread (ROIC-NNEP)	66.12%	-50.80%	-62.93%	-40.33%	-29.03%	0.43%	-18.95%
Return on Net Nonoperating Assets (RNNOA)	-57.27%	49.05%	56.24%	29.26%	18.42%	-0.26%	11.71%
Return on Equity (ROE)	6.20%	-4.11%	-7.56%	-16.56%	-14.54%	4.31%	-5.21%
Cash Return on Invested Capital (CROIC)	0.00%	11.28%	-237.24%	-98.29%	-38.26%	-10.73%	-21.83%
Operating Return on Assets (OROA)	6.18%	-2.34%	-8.89%	-16.01%	-15.09%	1.87%	-7.69%
Return on Assets (ROA)	7.42%	-3.68%	-6.94%	-14.76%	-12.76%	3.71%	-4.35%
Return on Common Equity (ROCE)	2.36%	-4.11%	-7.56%	-16.56%	-14.54%	4.31%	-5.21%
Return on Equity Simple (ROE_SIMPLE)	6.20%	-2.47%	-7.60%	-16.82%	-14.69%	4.00%	0.00%
Net Operating Profit after Tax (NOPAT)	7.23	-4.58	-28	-51	-48	7.34	-30
NOPAT Margin	13.94%	-7.31%	-29.82%	-37.21%	-21.65%	2.21%	-8.71%
Net Nonoperating Expense Percent (NNEP)	-2.65%	-2.36%	-0.88%	-5.49%	-3.94%	4.15%	2.03%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-12.78%	-12.16%	1.57%	-6.23%
Cost of Revenue to Revenue	14.09%	15.46%	16.82%	23.36%	20.47%	18.13%	20.63%
SG&A Expenses to Revenue	57.54%	76.83%	92.19%	104.35%	81.97%	60.24%	66.62%
R&D to Revenue	14.24%	21.16%	31.51%	32.77%	24.40%	15.67%	15.06%
Operating Expenses to Revenue	71.78%	94.98%	125.78%	129.81%	110.46%	79.26%	91.80%
Earnings before Interest and Taxes (EBIT)	4.40	-6.54	-40	-73	-68	9.23	-43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	6.68	-5.23	-37	-64	-61	19	-6.11
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.89	3.22	2.63	1.55	1.48	1.64	2.41
Price to Tangible Book Value (P/TBV)	6.89	3.22	3.36	2.27	2.12	2.14	3.06
Price to Revenue (P/Rev)	11.31	21.34	11.53	4.53	2.64	2.25	3.30
Price to Earnings (P/E)	196.20	0.00	0.00	0.00	0.00	40.91	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.51%	0.00%	0.00%	0.00%	0.00%	2.44%	0.00%
Enterprise Value to Invested Capital (EV/IC)	45.05	158.79	9.20	2.57	2.28	2.68	4.66
Enterprise Value to Revenue (EV/Rev)	9.89	14.80	8.02	2.64	1.54	1.40	2.46
Enterprise Value to EBITDA (EV/EBITDA)	76.84	0.00	0.00	0.00	0.00	24.99	0.00
Enterprise Value to EBIT (EV/EBIT)	116.75	0.00	0.00	0.00	0.00	50.22	0.00
Enterprise Value to NOPAT (EV/NOPAT)	70.98	0.00	0.00	0.00	0.00	63.16	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	73.15	93.99	0.00	0.00	0.00	7.14	13.15
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	954.29	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.30	0.00	0.00	0.00	0.00	0.02	0.02
Long-Term Debt to Equity	0.23	0.00	0.00	0.00	0.00	0.02	0.02
Financial Leverage	-0.87	-0.97	-0.89	-0.73	-0.63	-0.62	-0.62
Leverage Ratio	1.89	1.12	1.09	1.12	1.14	1.16	1.20
Compound Leverage Factor	2.31	1.74	1.09	1.06	0.96	2.72	0.83
Debt to Total Capital	22.79%	0.00%	0.00%	0.00%	0.00%	2.15%	2.09%
Short-Term Debt to Total Capital	5.29%	0.00%	0.00%	0.00%	0.00%	0.06%	0.09%
Long-Term Debt to Total Capital	17.50%	0.00%	0.00%	0.00%	0.00%	2.09%	2.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	77.21%	100.00%	100.00%	100.00%	100.00%	97.85%	97.91%
Debt to EBITDA	3.76	0.00	0.00	0.00	0.00	0.54	-1.64
Net Debt to EBITDA	-11.04	0.00	0.00	0.00	0.00	-15.27	47.34
Long-Term Debt to EBITDA	2.89	0.00	0.00	0.00	0.00	0.53	-1.58
Debt to NOPAT	3.48	0.00	0.00	0.00	0.00	1.37	-0.34
Net Debt to NOPAT	-10.20	0.00	0.00	0.00	0.00	-38.59	9.66
Long-Term Debt to NOPAT	2.67	0.00	0.00	0.00	0.00	1.33	-0.32
Altman Z-Score	11.13	34.95	13.29	7.68	5.59	6.80	6.74
Noncontrolling Interest Sharing Ratio	61.96%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	7.63	20.58	14.21	8.09	6.20	7.29	5.26
Quick Ratio	7.42	20.24	13.94	7.81	5.90	6.97	4.99
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	0.97	-104	-109	-55	-17	-39
Operating Cash Flow to CapEx	748.67%	207.77%	-546.59%	-766.14%	-41.34%	229.14%	178.86%
Free Cash Flow to Firm to Interest Expense	0.00	0.24	-104,323.30	-6,436.26	-5,020.81	-29.85	-449.58
Operating Cash Flow to Interest Expense	0.00	2.45	-18,983.00	-2,450.29	-511.45	112.42	748.22
Operating Cash Flow Less CapEx to Interest Expense	0.00	1.27	-22,456.00	-2,770.12	-1,748.55	63.36	329.90
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.73	0.22	0.21	0.30	0.49	0.67	0.62
Accounts Receivable Turnover	3.88	4.57	6.26	6.72	7.12	7.42	7.28
Inventory Turnover	6.90	5.61	7.47	10.67	7.55	7.49	7.73
Fixed Asset Turnover	28.90	0.00	0.00	11.51	11.06	8.68	4.63
Accounts Payable Turnover	4.41	4.89	6.81	8.80	6.00	7.01	5.55
Days Sales Outstanding (DSO)	94.08	79.84	58.27	54.28	51.30	49.20	50.15
Days Inventory Outstanding (DIO)	52.91	65.09	48.88	34.21	48.37	48.73	47.25
Days Payable Outstanding (DPO)	82.78	74.68	53.57	41.49	60.85	52.04	65.81
Cash Conversion Cycle (CCC)	64.21	70.25	53.59	47.00	38.81	45.89	31.60
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	11	5.84	82	141	148	173	181
Invested Capital Turnover	4.55	7.27	2.14	1.23	1.52	2.07	1.94
Increase / (Decrease) in Invested Capital	0.00	-5.55	76	58	7.65	25	8.70
Enterprise Value (EV)	513	927	755	362	338	463	846
Market Capitalization	587	1,337	1,085	620	581	746	1,135
Book Value per Share	$4.98	$20.88	$16.27	$15.15	$14.54	$16.28	$16.13
Tangible Book Value per Share	$4.98	$20.88	$12.76	$10.35	$10.18	$12.48	$12.72
Total Capital	110	416	412	399	391	466	481
Total Debt	25	0.00	0.00	0.00	0.00	10	10
Total Long-Term Debt	19	0.00	0.00	0.00	0.00	9.75	9.64
Net Debt	-74	-410	-330	-259	-243	-283	-289
Capital Expenditures (CapEx)	0.94	4.75	3.47	5.44	14	28	36
Debt-free, Cash-free Net Working Capital (DFCFNWC)	8.38	-1.13	-0.78	-2.47	4.87	18	-6.67
Debt-free Net Working Capital (DFNWC)	107	409	329	256	248	311	293
Net Working Capital (NWC)	101	409	329	256	248	311	292
Net Nonoperating Expense (NNE)	1.95	5.70	3.24	16	9.88	-11	-5.81
Net Nonoperating Obligations (NNO)	-74	-410	-330	-259	-243	-283	-289
Total Depreciation and Amortization (D&A)	2.28	1.31	3.41	9.18	6.84	9.31	37
Debt-free, Cash-free Net Working Capital to Revenue	16.16%	-1.81%	-0.82%	-1.80%	2.22%	5.39%	-1.94%
Debt-free Net Working Capital to Revenue	206.74%	652.39%	349.53%	186.92%	112.82%	93.67%	85.07%
Net Working Capital to Revenue	195.49%	652.39%	349.53%	186.92%	112.82%	93.58%	84.95%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.54)	($1.24)	($2.58)	($2.14)	$0.66	($0.83)
Adjusted Weighted Average Basic Shares Outstanding	0.00	18.93M	25.14M	26.05M	26.80M	27.78M	28.99M
Adjusted Diluted Earnings per Share	$0.00	($0.54)	($1.24)	($2.58)	($2.14)	$0.62	($0.83)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	18.93M	25.14M	26.05M	26.80M	29.26M	28.99M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	24.98M	25.41M	26.58M	27.45M	28.51M	29.73M
Normalized Net Operating Profit after Tax (NOPAT)	7.23	-4.58	-28	-64	-48	7.34	-30
Normalized NOPAT Margin	13.94%	-7.31%	-29.82%	-46.56%	-21.65%	2.21%	-8.71%
Pre Tax Income Margin	10.31%	-16.28%	-42.53%	-50.28%	-26.10%	6.49%	-8.57%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-1.62	-40,079.00	-4,285.59	-6,179.73	15.99	-496.12
NOPAT to Interest Expense	0.00	-1.14	-28,055.30	-2,999.91	-4,325.81	12.71	-348.45
EBIT Less CapEx to Interest Expense	0.00	-2.80	-43,552.00	-4,605.41	-7,416.82	-33.07	-914.44
NOPAT Less CapEx to Interest Expense	0.00	-2.31	-31,528.30	-3,319.74	-5,562.90	-36.35	-766.78
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-1.07%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Castle Biosciences' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	28,514,109.00	28,872,315.00	29,008,281.00	29,188,659.00	29,731,198.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	28,514,109.00	28,872,315.00	29,008,281.00	29,188,659.00	29,731,198.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-0.92	0.16	-0.02	-0.07	-0.48
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	66.15%	72.47%	73.59%	73.53%	39.50%	30.54%	20.57%	-0.94%	-3.19%	0.81%	-4.90%
EBITDA Growth	57.25%	80.76%	87.17%	134.62%	186.75%	301.40%	73.26%	-112.40%	-155.17%	-105.14%	-1,203.61%
EBIT Growth	55.24%	75.22%	82.64%	123.69%	152.69%	171.58%	-436.52%	-161.17%	-233.02%	-186.20%	42.68%
NOPAT Growth	55.24%	75.22%	82.64%	138.28%	120.62%	224.37%	-410.47%	-152.49%	-442.28%	-154.39%	34.09%
Net Income Growth	65.90%	87.49%	91.32%	147.50%	132.86%	471.71%	-920.05%	-49.29%	-122.08%	-124.32%	43.82%
EPS Growth	66.23%	89.74%	91.82%	144.29%	130.77%	500.00%	-900.00%	-51.61%	-125.00%	-118.75%	45.56%
Operating Cash Flow Growth	195.94%	409.78%	73.13%	733.86%	365.64%	31.09%	11.69%	-13.24%	-3.03%	10.53%	-266.62%
Free Cash Flow Firm Growth	84.53%	84.40%	63.65%	21.93%	19.99%	-69.16%	33.63%	-19.40%	-66.13%	42.06%	-233.37%
Invested Capital Growth	7.27%	5.44%	13.17%	13.67%	9.78%	16.57%	-2.10%	8.77%	10.67%	5.04%	23.69%
Revenue Q/Q Growth	22.65%	7.52%	10.37%	19.22%	-1.40%	0.62%	1.94%	-2.05%	-3.65%	4.78%	-3.83%
EBITDA Q/Q Growth	58.09%	49.30%	5.99%	273.29%	5.02%	17.72%	-112.48%	19.63%	-367.19%	89.02%	-3,063.27%
EBIT Q/Q Growth	54.44%	41.31%	3.31%	191.61%	1.34%	-20.26%	-824.77%	89.55%	-120.35%	48.33%	-381.92%
NOPAT Q/Q Growth	54.44%	41.31%	3.31%	248.03%	-75.46%	253.99%	-496.89%	84.78%	-60.06%	43.75%	-380.98%
Net Income Q/Q Growth	63.23%	62.64%	1.78%	452.01%	-74.56%	322.65%	-369.53%	117.50%	-111.08%	-365.47%	-522.73%
EPS Q/Q Growth	62.86%	69.23%	-12.50%	444.44%	-74.19%	300.00%	-381.25%	116.67%	-113.33%	-200.00%	-716.67%
Operating Cash Flow Q/Q Growth	232.38%	270.85%	-136.77%	451.10%	-2.75%	4.40%	-124.77%	444.95%	8.69%	19.00%	-182.17%
Free Cash Flow Firm Q/Q Growth	11.49%	33.02%	-106.66%	36.28%	9.29%	-41.61%	18.92%	-14.64%	-26.21%	50.61%	-366.47%
Invested Capital Q/Q Growth	1.81%	-5.04%	16.93%	0.56%	-1.68%	0.84%	-1.80%	11.71%	0.04%	-4.29%	15.64%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	81.59%	81.21%	80.96%	83.31%	81.80%	81.25%	81.38%	79.55%	77.48%	78.95%	75.46%
EBITDA Margin	-13.07%	-6.16%	-5.25%	7.63%	8.13%	9.51%	-1.16%	-0.95%	-4.63%	-0.49%	-15.95%
Operating Margin	-15.68%	-8.56%	-7.50%	5.76%	5.92%	4.69%	-31.74%	-4.93%	-8.19%	-4.40%	-22.00%
EBIT Margin	-15.68%	-8.56%	-7.50%	5.76%	5.92%	4.69%	-33.36%	-3.56%	-8.14%	-4.01%	-20.11%
Profit (Net Income) Margin	-11.23%	-3.90%	-3.47%	10.25%	2.65%	11.11%	-29.38%	5.25%	-0.60%	-2.68%	-17.35%
Tax Burden Percent	100.47%	101.53%	101.81%	113.11%	27.40%	121.62%	98.39%	-3,162.94%	129.79%	85.92%	100.76%
Interest Burden Percent	71.30%	44.91%	45.49%	157.34%	163.06%	194.69%	89.50%	4.66%	5.71%	77.74%	85.67%
Effective Tax Rate	0.00%	0.00%	0.00%	-13.11%	72.60%	-21.62%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-13.98%	-9.12%	-8.06%	11.45%	3.09%	11.81%	-44.98%	-6.57%	-10.92%	-5.99%	-27.59%
ROIC Less NNEP Spread (ROIC-NNEP)	-13.91%	-9.67%	-8.63%	10.08%	2.74%	10.04%	-42.46%	-9.48%	-12.48%	-6.11%	-26.96%
Return on Net Nonoperating Assets (RNNOA)	8.65%	6.14%	5.05%	-5.97%	-1.66%	-6.24%	25.19%	5.56%	7.52%	3.77%	15.62%
Return on Equity (ROE)	-5.33%	-2.98%	-3.01%	5.48%	1.44%	5.58%	-19.80%	-1.01%	-3.40%	-2.21%	-11.97%
Cash Return on Invested Capital (CROIC)	-46.56%	-38.26%	-30.34%	-19.53%	-9.67%	-10.73%	-3.51%	-17.27%	-23.68%	-21.83%	-33.46%
Operating Return on Assets (OROA)	-6.74%	-4.18%	-4.25%	3.63%	3.89%	3.17%	-24.12%	-2.39%	-5.19%	-2.49%	-13.02%
Return on Assets (ROA)	-4.82%	-1.90%	-1.97%	6.46%	1.74%	7.49%	-21.24%	3.52%	-0.38%	-1.66%	-11.24%
Return on Common Equity (ROCE)	-5.33%	-2.98%	-3.01%	5.48%	1.44%	5.58%	-19.80%	-1.01%	-3.40%	-2.21%	-11.97%
Return on Equity Simple (ROE_SIMPLE)	-19.57%	0.00%	-7.65%	-0.73%	1.38%	0.00%	-1.15%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-6.75	-3.96	-3.83	5.67	1.39	4.93	-20	-2.98	-4.76	-2.68	-13
NOPAT Margin	-10.97%	-5.99%	-5.25%	6.52%	1.62%	5.71%	-22.22%	-3.45%	-5.74%	-3.08%	-15.40%
Net Nonoperating Expense Percent (NNEP)	-0.06%	0.55%	0.56%	1.37%	0.35%	1.77%	-2.52%	2.91%	1.56%	0.12%	-0.63%
Return On Investment Capital (ROIC_SIMPLE)	-	-1.01%	-	-	-	1.06%	-4.34%	-0.64%	-1.00%	-0.56%	-2.73%
Cost of Revenue to Revenue	18.41%	18.79%	19.04%	16.69%	18.20%	18.75%	18.62%	20.45%	22.52%	21.05%	24.54%
SG&A Expenses to Revenue	72.56%	66.68%	66.46%	58.72%	58.87%	57.89%	66.62%	67.37%	67.32%	65.20%	77.56%
R&D to Revenue	21.02%	19.65%	18.92%	16.25%	14.37%	13.64%	14.31%	14.84%	15.61%	15.53%	17.24%
Operating Expenses to Revenue	97.27%	89.77%	88.46%	77.55%	75.88%	76.56%	113.12%	84.48%	85.67%	83.35%	97.46%
Earnings before Interest and Taxes (EBIT)	-9.64	-5.66	-5.47	5.01	5.08	4.05	-29	-3.07	-6.76	-3.49	-17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-8.04	-4.07	-3.83	6.64	6.97	8.21	-1.02	-0.82	-3.85	-0.42	-13
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.17	1.48	1.48	1.42	1.79	1.64	1.30	1.29	1.41	2.41	1.58
Price to Tangible Book Value (P/TBV)	1.70	2.12	2.07	1.93	2.39	2.14	1.58	1.68	1.81	3.06	2.00
Price to Revenue (P/Rev)	2.36	2.64	2.38	2.09	2.54	2.25	1.64	1.70	1.92	3.30	2.15
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	131.56	40.91	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.76%	2.44%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.43	2.28	2.12	2.02	3.04	2.68	1.77	1.71	2.02	4.66	2.28
Enterprise Value to Revenue (EV/Rev)	1.16	1.54	1.46	1.22	1.67	1.40	0.86	0.93	1.12	2.46	1.41
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	91.40	24.99	14.06	23.32	124.85	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	50.22	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	63.16	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	28.27	8.62	8.82	7.14	4.57	5.18	6.20	13.15	9.91
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
Long-Term Debt to Equity	0.00	0.00	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
Financial Leverage	-0.62	-0.63	-0.59	-0.59	-0.60	-0.62	-0.59	-0.59	-0.60	-0.62	-0.58
Leverage Ratio	1.12	1.14	1.12	1.14	1.15	1.16	1.14	1.17	1.19	1.20	1.16
Compound Leverage Factor	0.80	0.51	0.51	1.79	1.87	2.26	1.02	0.05	0.07	0.93	1.00
Debt to Total Capital	0.00%	0.00%	2.42%	2.31%	2.22%	2.15%	2.23%	2.16%	2.11%	2.09%	2.14%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.06%	0.25%	0.42%	0.00%	0.09%	0.35%
Long-Term Debt to Total Capital	0.00%	0.00%	2.42%	2.31%	2.22%	2.09%	1.98%	1.74%	2.11%	2.00%	1.78%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	97.58%	97.69%	97.78%	97.85%	97.77%	97.84%	97.89%	97.91%	97.87%
Debt to EBITDA	0.00	0.00	-0.28	-1.08	1.76	0.54	0.47	0.72	3.28	-1.64	-0.55
Net Debt to EBITDA	0.00	0.00	6.53	26.84	-47.30	-15.27	-12.68	-19.15	-90.45	47.34	13.65
Long-Term Debt to EBITDA	0.00	0.00	-0.28	-1.08	1.76	0.53	0.42	0.58	3.28	-1.58	-0.46
Debt to NOPAT	0.00	0.00	-0.34	-0.91	-17.69	1.37	-1.04	-0.62	-0.41	-0.34	-0.43
Net Debt to NOPAT	0.00	0.00	7.81	22.64	476.49	-38.59	28.05	16.48	11.35	9.66	10.80
Long-Term Debt to NOPAT	0.00	0.00	-0.34	-0.91	-17.69	1.33	-0.92	-0.50	-0.41	-0.32	-0.36
Altman Z-Score	5.75	6.04	6.90	6.39	7.23	6.76	6.19	4.66	4.80	6.97	5.59
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.70	6.20	9.25	8.12	7.78	7.29	9.37	6.85	6.47	5.26	6.75
Quick Ratio	7.34	5.90	8.82	7.75	7.45	6.97	8.89	6.45	6.09	4.99	6.23
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-17	-12	-24	-15	-14	-20	-16	-18	-23	-11	-53
Operating Cash Flow to CapEx	204.32%	490.42%	-74.72%	459.12%	366.14%	322.29%	-127.58%	225.07%	152.76%	375.14%	-177.77%
Free Cash Flow to Firm to Interest Expense	-8,663.50	-5,802.80	-1,713.19	-56.61	-68.97	-213.39	-936.33	-868.99	-959.62	-474.00	-396.01
Operating Cash Flow to Interest Expense	2,506.00	9,293.50	-488.21	88.88	116.11	264.84	-355.06	991.48	942.96	1,122.13	-165.14
Operating Cash Flow Less CapEx to Interest Expense	1,279.50	7,398.50	-1,141.57	69.52	84.40	182.66	-633.35	550.95	325.67	823.00	-258.04
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.43	0.49	0.57	0.63	0.66	0.67	0.72	0.67	0.64	0.62	0.65
Accounts Receivable Turnover	6.42	7.12	7.12	7.44	7.15	7.42	7.01	7.05	6.89	7.28	6.89
Inventory Turnover	8.79	7.55	8.01	7.38	9.15	7.49	8.65	8.03	9.05	7.73	8.69
Fixed Asset Turnover	10.87	11.06	9.80	9.72	9.36	8.68	7.86	0.00	5.32	4.63	4.35
Accounts Payable Turnover	6.63	6.00	5.05	6.26	8.22	7.01	7.04	5.79	7.24	5.55	6.39
Days Sales Outstanding (DSO)	56.88	51.30	51.26	49.05	51.06	49.20	52.08	51.81	52.99	50.15	52.95
Days Inventory Outstanding (DIO)	41.51	48.37	45.59	49.46	39.90	48.73	42.19	45.43	40.32	47.25	42.02
Days Payable Outstanding (DPO)	55.07	60.85	72.26	58.35	44.42	52.04	51.87	63.02	50.39	65.81	57.15
Cash Conversion Cycle (CCC)	43.32	38.81	24.60	40.16	46.54	45.89	42.40	34.22	42.93	31.60	37.82
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	156	148	173	174	171	173	170	189	190	181	210
Invested Capital Turnover	1.27	1.52	1.54	1.76	1.91	2.07	2.02	1.90	1.90	1.94	1.79
Increase / (Decrease) in Invested Capital	11	7.65	20	21	15	25	-3.63	15	18	8.70	40
Enterprise Value (EV)	223	338	367	351	521	463	300	324	383	846	478
Market Capitalization	453	581	596	601	791	746	571	590	661	1,135	730
Book Value per Share	$14.39	$14.54	$14.64	$15.35	$15.90	$16.28	$15.44	$15.77	$16.10	$16.13	$15.52
Tangible Book Value per Share	$9.93	$10.18	$10.46	$11.27	$11.92	$12.48	$12.71	$12.17	$12.59	$12.72	$12.25
Total Capital	386	391	412	434	451	466	450	465	477	481	471
Total Debt	0.00	0.00	10	10	10	10	10	10	10	10	10
Total Long-Term Debt	0.00	0.00	10	10	10	9.75	8.92	8.10	10	9.64	8.40
Net Debt	-230	-243	-229	-250	-270	-283	-271	-266	-277	-289	-252
Capital Expenditures (CapEx)	2.45	3.79	9.15	5.23	6.37	7.56	4.73	9.25	15	7.18	12
Debt-free, Cash-free Net Working Capital (DFCFNWC)	14	4.87	25	21	21	18	38	24	15	-6.67	20
Debt-free Net Working Capital (DFNWC)	243	248	264	281	300	311	313	300	302	293	282
Net Working Capital (NWC)	243	248	264	281	300	311	312	298	302	292	280
Net Nonoperating Expense (NNE)	0.16	-1.38	-1.30	-3.25	-0.88	-4.66	6.30	-7.50	-4.26	-0.35	1.64
Net Nonoperating Obligations (NNO)	-230	-243	-229	-250	-270	-283	-271	-266	-277	-289	-252
Total Depreciation and Amortization (D&A)	1.61	1.58	1.64	1.63	1.89	4.16	28	2.24	2.91	3.07	3.48
Debt-free, Cash-free Net Working Capital to Revenue	7.05%	2.22%	9.81%	7.39%	6.63%	5.39%	10.97%	6.87%	4.28%	-1.94%	5.92%
Debt-free Net Working Capital to Revenue	126.71%	112.82%	105.22%	97.69%	96.34%	93.67%	90.25%	86.56%	87.99%	85.07%	82.90%
Net Working Capital to Revenue	126.71%	112.82%	105.22%	97.69%	96.34%	93.58%	89.92%	86.00%	87.99%	84.95%	82.41%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.26)	($0.08)	($0.09)	$0.32	$0.08	$0.35	($0.90)	$0.16	($0.02)	($0.07)	($0.49)
Adjusted Weighted Average Basic Shares Outstanding	26.83M	26.80M	27.49M	27.65M	27.84M	27.78M	28.61M	28.91M	29.07M	28.99M	29.89M
Adjusted Diluted Earnings per Share	($0.26)	($0.08)	($0.09)	$0.31	$0.08	$0.32	($0.90)	$0.15	($0.02)	($0.06)	($0.49)
Adjusted Weighted Average Diluted Shares Outstanding	26.83M	26.80M	27.49M	28.74M	29.40M	29.26M	28.61M	29.55M	29.07M	28.99M	29.89M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	26.91M	27.45M	27.61M	27.74M	28.01M	28.51M	28.87M	29.01M	29.19M	29.73M	30.33M
Normalized Net Operating Profit after Tax (NOPAT)	-6.75	-3.96	-3.83	3.51	3.56	2.84	-20	-2.98	-4.76	-2.68	-13
Normalized NOPAT Margin	-10.97%	-5.99%	-5.25%	4.03%	4.14%	3.28%	-22.22%	-3.45%	-5.74%	-3.08%	-15.40%
Pre Tax Income Margin	-11.18%	-3.84%	-3.41%	9.06%	9.65%	9.14%	-29.86%	-0.17%	-0.46%	-3.12%	-17.22%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-4,820.00	-2,829.00	-390.79	18.56	25.27	44.02	-1,726.65	-146.00	-281.50	-145.46	-125.55
NOPAT to Interest Expense	-3,374.00	-1,980.30	-273.55	21.00	6.92	53.54	-1,149.98	-141.70	-198.45	-111.62	-96.16
EBIT Less CapEx to Interest Expense	-6,046.50	-4,724.00	-1,044.14	-0.80	-6.44	-38.15	-2,004.94	-586.52	-898.79	-444.58	-218.45
NOPAT Less CapEx to Interest Expense	-4,600.50	-3,875.30	-926.91	1.64	-24.79	-28.63	-1,428.27	-582.22	-815.74	-410.75	-189.05
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Castle Biosciences (NASDAQ: CSTL) showed a mixed but generally pressured financial picture in Q1 2026, with revenue holding up better than profitability and cash flow. The company generated $83.7 million in revenue, essentially flat with the prior quarter and slightly below the year-ago period, but it still posted a loss as operating expenses remained too high relative to gross profit. On the brighter side, Castle Biosciences still has a large liquidity cushion, supported by cash and investments, which gives it time to work through the current earnings pressure.

Top takeaways from the last several years:

Castle Biosciences continues to generate substantial gross profit, with Q1 2026 gross profit of $63.1 million on $83.7 million of revenue, showing the core testing business still produces healthy margins before operating expenses.
The balance sheet remains strong, with $63.8 million in cash and $197.9 million in short-term investments at the end of Q1 2026, giving the company significant financial flexibility.
Total current assets of $328.9 million still comfortably exceed total current liabilities of $48.8 million, indicating solid near-term liquidity.
Operating cash flow was positive in several prior quarters, including Q4 2025 and Q3 2025, showing the business can still produce cash when working capital movements are favorable.
Revenue has generally stayed in a relatively stable range over the past year, with quarterly sales mostly around the low-to-mid $80 million level.
Interest and investment income has provided a meaningful offset to operating losses, especially in 2025 when investment income helped soften pre-tax losses.
Q1 2026 revenue of $83.7 million was only modestly below Q4 2025’s $87.0 million, suggesting demand has been fairly steady rather than collapsing.
Shares outstanding have increased over time, which is a mild dilution headwind for per-share results.
Goodwill and other intangible-type assets remain material on the balance sheet, so investors should continue to watch for any impairment risk if growth slows further.
Q1 2026 operating income was a loss of $18.4 million, meaning overhead is still too high for the current revenue base.
Selling, general and administrative expense was $65.0 million in Q1 2026, nearly matching gross profit and leaving little room for bottom-line profitability.
Q1 2026 net cash from operations was negative $22.1 million, a sharp reversal from the positive operating cash flow seen in late 2025.
Cash and equivalents fell from $85.6 million in Q3 2025 to $63.8 million in Q1 2026, reflecting the recent cash burn.
The company reported net losses in Q1 2026, Q4 2025, and Q3 2025, showing that profitability has been inconsistent despite strong gross profit.
Working capital swings continue to be a drag, as changes in operating assets and liabilities reduced cash by $19.7 million in Q1 2026.
Compared with 2024, earnings power has weakened considerably; Castle Biosciences moved from occasional profitable quarters to a more persistent loss profile in 2025 and early 2026.

Bottom line: Castle Biosciences has a strong balance sheet and a business that still generates healthy gross profit, but the company is currently struggling to convert that into durable operating profitability. For retail investors, the key question is whether management can rein in SG&A and restore consistent positive operating cash flow before cash reserves start to shrink materially.

07/11/26 10:47 PM ETAI Generated. May Contain Errors.

Castle Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Castle Biosciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Castle Biosciences' net income appears to be on an upward trend, with a most recent value of -$24.16 million in 2025, falling from $5.28 million in 2019. The previous period was $18.25 million in 2024. View Castle Biosciences' forecast to see where analysts expect Castle Biosciences to go next.

Castle Biosciences' total operating income in 2025 was -$42.81 million, based on the following breakdown:

Total Gross Profit: $273.20 million
Total Operating Expenses: $316.01 million

Over the last 6 years, Castle Biosciences' total revenue changed from $51.87 million in 2019 to $344.23 million in 2025, a change of 563.7%.

Castle Biosciences' total liabilities were at $107.68 million at the end of 2025, a 42.8% increase from 2024, and a 231.6% increase since 2018.

In the past 7 years, Castle Biosciences' cash and equivalents has ranged from $4.48 million in 2018 to $409.85 million in 2020, and is currently $116.73 million as of their latest financial filing in 2025.

Over the last 6 years, Castle Biosciences' book value per share changed from 4.98 in 2019 to 16.13 in 2025, a change of 223.6%.

Related Companies

Financial statements for NASDAQ:CSTL last updated on 6/26/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Castle Biosciences (CSTL) Financials

Financials Breakdown Chart

Key Financial Trends

Castle Biosciences Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Castle Biosciences (CSTL) Financials

Annual Income Statements for Castle Biosciences

Quarterly Income Statements for Castle Biosciences

Annual Cash Flow Statements for Castle Biosciences

Quarterly Cash Flow Statements for Castle Biosciences

Annual Balance Sheets for Castle Biosciences

Quarterly Balance Sheets for Castle Biosciences

Annual Metrics And Ratios for Castle Biosciences

Quarterly Metrics And Ratios for Castle Biosciences

Financials Breakdown Chart

Key Financial Trends

Castle Biosciences Financials - Frequently Asked Questions

When does Castle Biosciences' fiscal year end?

How has Castle Biosciences' net income changed over the last 6 years?

What is Castle Biosciences' operating income?

How has Castle Biosciences' revenue changed over the last 6 years?

How much debt does Castle Biosciences have?

How much cash does Castle Biosciences have?

How has Castle Biosciences' book value per share changed over the last 6 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools